StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.85+0.41 (+1.49%)

Close on Nov 17, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Cogent Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$307.55M. For fiscal 2025 it was -$264.44M. The highest annual figure on record is -$25.84M in fiscal 2017.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$264.44M–
FY2024Dec 31, 2024-$207.79M–
FY2023Dec 31, 2023-$153.62M–
FY2022Dec 31, 2022-$118.64M–
FY2021Dec 31, 2021-$58.76M–
FY2020Dec 31, 2020-$35.85M–
FY2019Dec 31, 2019-$41.51M–
FY2018Dec 31, 2018-$32.49M–
FY2017Dec 31, 2017-$25.84M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$77.27M–
Q1 FY2026Mar 31, 2026-$86.88M–
Q4 FY2025Dec 31, 2025-$79.11M–
Q3 FY2025Sep 30, 2025-$64.29M–
Q2 FY2025Jun 30, 2025-$54.54M–
Q1 FY2025Mar 31, 2025-$66.51M–
Q4 FY2024Dec 31, 2024-$60.58M–
Q3 FY2024Sep 30, 2024-$51.98M–
Q2 FY2024Jun 30, 2024-$42.70M–
Q1 FY2024Mar 31, 2024-$52.53M–
Q4 FY2023Dec 31, 2023-$44.07M–
Q3 FY2023Sep 30, 2023-$37.97M–
Q2 FY2023Jun 30, 2023-$32.07M–
Q1 FY2023Mar 31, 2023-$39.52M–
Q4 FY2022Dec 31, 2022-$29.41M–
Q3 FY2022Sep 30, 2022-$34.44M–
Q2 FY2022Jun 30, 2022-$26.46M–
Q1 FY2022Mar 31, 2022-$28.33M–
Q4 FY2021Dec 31, 2021-$20.78M–
Q3 FY2021Sep 30, 2021-$14.11M–
Q2 FY2021Jun 30, 2021-$12.51M–
Q1 FY2021Mar 31, 2021-$11.37M–
Q4 FY2020Dec 31, 2020-$9.37M–
Q3 FY2020Sep 30, 2020-$10.27M–
Q2 FY2020Jun 30, 2020-$8.32M–
Q1 FY2020Mar 31, 2020-$7.89M–
Q4 FY2019Dec 31, 2019-$8.45M–
Q3 FY2019Sep 30, 2019-$10.21M–
Q2 FY2019Jun 30, 2019-$11.34M–
Q1 FY2019Mar 31, 2019-$11.52M–
Q4 FY2018Dec 31, 2018-$9.02M–
Q3 FY2018Sep 30, 2018-$7.58M–
Q2 FY2018Jun 30, 2018-$7.91M–
Q1 FY2018Mar 31, 2018-$7.98M–
Q4 FY2017Dec 31, 2017-$6.52M–
Q3 FY2017Sep 30, 2017-$6.29M–
Q2 FY2017Jun 30, 2017-$5.76M–
Q1 FY2017Mar 31, 2017-$7.27M–

More Cogent Biosciences figures

See a number that looks wrong?